Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRINT: EDP-235 in Mild or Moderate COVID-19
NCT05616728Phase 2Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Nov 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of zevotrelvir in coronavirus disease 2019 (COVID-19), sponsored by Enanta Pharmaceuticals. Started Nov 2022; status: completed.
02
Drugs
zevotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05616728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05616728.